Acción SONN SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Sonnet BioTherapeutics Holdings, Inc.

Acciones

SONN

US83548R3030

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:30:01 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,9319 USD +1,29 % Gráfico intradía de Sonnet BioTherapeutics Holdings, Inc. -39,09 % -46,44 %
20/06 Principales caídas del mediodía MT
13/06 Sonnet BioTherapeutics Holdings, Inc. Anuncia la generación y caracterización de dos novedosos candidatos a fármacos inmunoterapéuticos en fase de desarrollo, SON-1411 y SON-1400, cada uno de los cuales contiene una variante del dominio IL-18 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Top Midday Decliners
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics Holdings, Inc. Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
Top Premarket Gainers
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SONN
  4. Noticias Sonnet BioTherapeutics Holdings, Inc.
  5. Otros idiomas